Global Congenital Adrenal Hyperplasia Analysis 2025, Forecast To 2034
26 Mar, 2025
What Has Been The Evolution of the Congenital Adrenal Hyperplasia Market in Recent Years?
The congenital adrenal hyperplasia market has seen considerable growth due to a variety of factors.
• The market for congenital adrenal hyperplasia has seen significant growth in recent times. An expansion from $0.47 billion in 2024 to $0.50 billion in 2025, representing a compound annual growth rate (CAGR) of 7.3%, is projected.
The upsurge in the past can be linked to factors such as an increased occurrence of congenital adrenal hyperplasia, growing acceptance of corticosteroid treatments, escalated healthcare spending, a heightened emphasis on pediatric care, and advanced government action and reimbursement strategies.
How Will the Congenital Adrenal Hyperplasia Market Size?
The congenital adrenal hyperplasia market is expected to maintain its strong growth trajectory in upcoming years.
• In the forthcoming years, the market size for congenital adrenal hyperplasia is predicted to experience robust growth, climbing to a value of $0.66 billion in 2029, exhibiting a compound annual growth rate (CAGR) of 7.1%.
This predicted expansion during the forecast period can be ascribed to factors such as the bourgeoning demand for personalised medicine, the escalating prevalence of genetic ailments, intensified research into treatments for congenital adrenal hyperplasia, augmented investment in healthcare, and the growing use of telemedicine in handling congenital adrenal hyperplasia. Expectations for the forecast period further include enhancements in healthcare infrastructure, improvements in molecular diagnostics, progresion in enzyme replacement therapies, formulation of long-acting corticosteroids, and evolution in genetic screening procedures.
Which Drivers Are Accelerating Growth In The Congenital Adrenal Hyperplasia Market?
The congenital adrenal hyperplasia market growth is projected to skyrocket due to the increasing demand for gene therapy. This medical approach, which modifies or manipulates a person's genes for disease treatment or prevention, is seeing a surge in popularity due to breakthroughs in genetic research and biotechnology. These advancements allow for more accurate, specifically-targeted treatments for genetic disorders, cancers, and other long-term illnesses. In the context of congenital adrenal hyperplasia (CAH), a disorder caused by gene mutations disturbing adrenal hormone production, gene therapy presents possibilities of targeted genetic interventions to fix the genetic flaws and reestablish regular hormone function. For example, the American Society of Gene and Cell Therapy (ASGCT), a professional membership organization based in the United States, reported in April 2024, that out of 1,023 gene therapies being developed for rare diseases, eight out of the top 10 rare diseases were cancer-related. The second quarter of 2024 started with 76 gene therapy trials, marking a 25% increase compared to the last quarter. Hence, the growing demand for gene therapy is stimulating the expansion of the congenital adrenal hyperplasia market.
What Key Areas Define The Segmentation Of The Global Congenital Adrenal Hyperplasia Market?
The congenital adrenal hyperplasia market covered in this report is segmented –
1) By Type: Classic Congenital Adrenal Hyperplasia, Non-Classic Congenital Adrenal Hyperplasia
2) By Treatment And Diagnosis: Diagnosis, Treatment
3) By End-Use: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Research Institutes
Subsegments:
1) By Classic Congenital Adrenal Hyperplasia: Salt-Wasting Classic Congenital Adrenal Hyperplasia, Simple Virilizing Classic Congenital Adrenal Hyperplasia
2) By Non-Classic Congenital Adrenal Hyperplasia: Late-Onset Non-Classic Congenital Adrenal Hyperplasia, Mild Non-Classic Congenital Adrenal Hyperplasia
How Are Emerging Trends Reshaping The Dynamics Of The Congenital Adrenal Hyperplasia Market?
Key players in the congenital adrenal hyperplasia market are honing in on the creation of new treatments like CRF1 receptor antagonists. These are tailored to control cortisol production and decrease excessive adrenal androgen. CRF1 receptor antagonist is a form of medication that inhibits the corticotropin-releasing factor 1 (CRF1) receptor to manage the body's stress response and mitigate excessive adrenal androgen production, which is linked with congenital adrenal hyperplasia. For example, Neurocrine Biosciences, Inc., a biopharmaceutical company based in the US, was granted FDA approval for crenessity (crinecerfont) in December 2024. This novel treatment for congenital adrenal hyperplasia (CAH), the first in 70 years, is an orally-administered medication that selectively targets corticotropin-releasing factor type 1 receptors. It efficiently curbs excess adrenocorticotropic hormone (ACTH) and adrenal androgens and enables the reduction of glucocorticoid doses. The approval decision was informed by the data from the CAHtalyst Phase 3 trials that demonstrated a notable efficacy in reducing androgen levels. The forthcoming availability of Crenessity signifies a substantial progression in CAH treatment.
Who Are the Key Players In The Congenital Adrenal Hyperplasia Market?
Major companies operating in the congenital adrenal hyperplasia market are:
• Pfizer Inc.
• Sanofi S.A.
• Thermo Fisher Scientific Inc.
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Eton Pharmaceuticals Inc
• Teva Pharmaceutical Industries
• Macleods Pharmaceuticals
• H. Lundbeck A/S
• Neurocrine Biosciences Inc.
• BridgeBio Pharma Inc
• Regenxbio Inc.
• Millendo Therapeutics Inc.
• Applied Therapeutics. Inc.
• OMass Therapeutics Limited
• ViennaLab Diagnostics GmbH
• EffRx Pharmaceuticals SA
• Adrenas Therapeutics Inc
• HBM Alpha Therapeutics
• Spruce Biosciences Inc.
• Crinetics Pharmaceuticals Inc.
What Is The Most Dominant Region In The Congenital Adrenal Hyperplasia Market?
North America was the largest region in the congenital adrenal hyperplasia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the congenital adrenal hyperplasia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.